Stocktoria
Solid Biosciences Inc. SLDB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-01-26
Solid Biosciences Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M |
| R&D expense | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Operating cash flow | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M |
| Cash & equivalents | $59.9M | $80.2M | $74.0M | $155.4M | $119.1M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
| Shareholders' equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M |
| EPS (diluted) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.14 |
Source: SEC EDGAR filings · CIK 0001707502 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.